Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue Iron Investing
Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids Iron Investing
CuFe Ltd to Present at the Australian Rare Earths & Critical Minerals Virtual Investor Conference November 19th Precious Metals Investing
LABRADOR IRON ORE ROYALTY CORPORATION - RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025 Iron Investing
Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation Iron Investing
